Indexed with PubMed and Science Citation Index (E) 
Users online: 245 
     Home | Feedback | Login 
About Current Issue Archive Ahead of print Search Instructions Online Submission Subscribe What's New Contact  
  Navigate here 
   Next article
   Previous article 
   Table of Contents
 Resource links
   Similar in PUBMED
    Search Pubmed for
    Search in Google Scholar for
  Related articles
   Article in PDF (923 KB)
   Citation Manager
   Access Statistics
   Reader Comments
   Email Alert *
   Add to My List *
* Registration required (free)  

  In this article
   Case Report

 Article Access Statistics
    PDF Downloaded0    
    Comments [Add]    

Recommend this journal


Year : 1998  |  Volume : 64  |  Issue : 2  |  Page : 93-94

Malignant atrophic papulosis

Department of Dermato-Venereology, Rajindra Hospital, Patiala(Punjab)-147001, India

Correspondence Address:
Radha Rani Mittal
97, New Lal Bagh, Patiala (Punjab)-147001
Login to access the Email id

Source of Support: None, Conflict of Interest: None

PMID: 20921728

Rights and PermissionsRights and Permissions


Malignant atrophic papulosis (MAP) is a rare disorder and only a few cases have been reported in blacks and Asians. A 38-year old male with typical cutaneous lesions of MAP which were confirmed histopathologically is reported.

How to cite this article:
Mittal RR, Bansal N, Gupta S. Malignant atrophic papulosis. Indian J Dermatol Venereol Leprol 1998;64:93-4

How to cite this URL:
Mittal RR, Bansal N, Gupta S. Malignant atrophic papulosis. Indian J Dermatol Venereol Leprol [serial online] 1998 [cited 2020 Nov 28];64:93-4. Available from:

  Introduction Top

Malignant atrophic papulosis (MAP) is a rare fatal endovasculitis of unknown cause affecting skin, gut and CNS.[1] Crops of asymptomatic, numerous, erythematous papules, nodules with porcelain-white central atrophy and telangiectatic borders appear slowly for years anywhere except face, palms and soles.[2,3] Skin lesions are followed by gut lesions within 3 years.[3] In some cases it is confined to the skin.[4] Histopathologically typical chronic non ulcerative lesions show thin atrophic epidermis, complete dermal fibrosis with acellularity, and mild perivascular cuffing/obliteration of dermal vessels. Abundant mucin is seen in early lesions and only towards margins in late plaques.[5] Fibrinolytic activity is absent only in lesions but present normally in peripheral healthy skin.[6] MAP is thought to be a hypercoagulation syndrome with inhibited fibrinolysis.[7] Recently lymphocytemediated vasculitis was reported in the pathogenesis of MAP.[8]

  Case Report Top

A 38-year-old man developed two asymptomatic, atrophic plaques, one on the left upper arm (20x15cm) and the other on the left lower leg (15x15) and was diagnosed as a case of leprosy at the periphery and treated with MDT. He took regular therapy for 11/2 years without any relief and numerous new lesions erupted slowly over the trunk, limbs and face during MDT. There was no history of constitutional symptoms or systemic involvement including pain abdomen. In addition to above two big atrophic plaques, innumerable variable-sized scars were seen on the limbs, trunk and face. Most scars were depressed, porcelain white with telangiectatic borders, while others were depressed pigmented scars. Five, firm, asymptomatic, nontender, erythematous nodules with typical porcelain-white centres, finely wrinkled surface and ill-defined margins were seen on the trunk. Multiple, bilateral asymmetrical, 2-6 mm, erythematous shiny papules, some with pinpoint porcelain-white centres covered lateral side of cheeks, rim of pinnae, and neck. General physical and systemic examinations were normal except splenomegaly (2 cm below costal margin). Eyes were normal. Histopathologically diagnosis of MAP was confirmed as marked atrophy of epidermis, necrosis and acellular dermis in wedge shaped pattern was seen along with endovasculitis and mild perivascular mononuclear infiltration. Routine laboratory tests on blood and urine were normal. LFT, RFT serum electrolytes, and x-ray of the chest were normal. L.E cell phenomenon was negative. Ultrasonogram of abdomen confirmed splenomegaly.

Patient was treated with aspirin (1050 mg) and dipyridamole (150 mg) daily for 10 weeks. No new lesion appeared after starting therapy.

  Discussion Top

Probably this is the first case of MAP in the Indian literature. Face was predominantly affected in our patient but in earlier literature, involvement of face was not observed. MAP is considered a fatal disease but some patients may survive for long as disease remains localized only to skin[4], and in our patient also lesions were limited to skin since 2 1/2 years. Therapy with aspirin and dipyridamole was effective as telangiectasia disappeared and new lesions did not erupt after it.


Print this article  Email this article
Previous article Next article


Online since 15th March '04
Published by Wolters Kluwer - Medknow